Kibur Medical Presents Preliminary Clinical Data on Intratumoral Microdosing of High Grade Gliomas at the American Academy of Cancer Research in Orlando, FL
BOSTON (PRWEB) April 13, 2023 -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present a poster at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing a recent clinical application of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific mono- and combination therapies. This deep molecular profiling of the drug-tumor response identifies biomarkers of drug activity and enables prediction of drug response. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in tumor models.
The poster, #LB290, titled “Intracranial, Intratumoral Drug-releasing Microdevices in Patients with High Grade Gliomas may Identify Biomarkers of Drug Activity and Predict Tumor Response to Systemic Chemotherapy”, will be presented on April 19th from 9:00 a.m. – 12:00 EST.
“Our recent clinical data presented at AACR demonstrates that our technology can analyze multiple chemotherapies in combination in high grade gliomas.“ said Professor Oliver Jonas, Kibur’s Scientific Founder. “We are excited about this approach to help close the translational gap in cancer care and further our mission to advance precision medicine for better patient outcomes.”
In addition to the poster presentations, Kibur Medical will be available to further discuss their technology and how it may be incorporated into a variety of cancer models and applications at Booth #2242.
Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.
About Kibur Medical
Kibur Medical intends to fundamentally disrupt oncology drug development and patient treatment outcomes by application of a validated and proprietary, in vivo pathology-driven technology that brings the laboratory to the patient that allows drug developers to accelerate and de-risk their development programs and clinicians to prescribe with evidence-based medicine the right drug to the right patient for better patient outcomes. Visit our website at https://kiburmed.com to learn more.
Contact:
Jennifer M Rossi, PhD
CEO, Operation-All.com
+1.617.203.6103
Jennifer Rossi, Operation-All, http://www.kiburmed.com, 1 617-203-6103, [email protected]
Share this article